Evidence map›Paper›PMID 26704178›Full record

ReviewBiochimica et biophysica acta2016

Vascular cognitive impairment: Modeling a critical neurologic disease in vitro and in vivo.

Alex M Helman, M Paul Murphy

Open access · greenAbstract readReview
In one paragraph

Review in Biochimica et biophysica acta, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 54 citations in OpenAlex.

  1. Current updates on latest basic research of scientific relevance in hypertensive dementia.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Asymmetric dimethylarginine exacerbates cognitive dysfunction associated with cerebrovascular pathology.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020
    Article
  17. Article
  18. Article
  19. Animal Models of Chronic Cerebral Hypoperfusion: From Mouse to Primate.International journal of molecular sciences · 2019
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Alex M HelmanDepartment of Molecular and Cellular Biochemistry, University of Kentucky, 800 South Limestone, Lexington, KY 40536, USA; Sanders-Brown Center on Aging, University of Kentucky, 800 South Limestone, Lexington, KY 40536, USA.
M Paul MurphyDepartment of Molecular and Cellular Biochemistry, University of Kentucky, 800 South Limestone, Lexington, KY 40536, USA; Sanders-Brown Center on Aging, University of Kentucky, 800 South Limestone, Lexington, KY 40536, USA. Electronic address: Michael.Murphy@uky.edu.
University of Kentucky · US

Funding

Lead Exposure in a Novel Mouse Model of Neurologic DiseaseR21ES024158 · NIEHS · UNIVERSITY OF KENTUCKY · PI MURPHY, MICHAEL PAUL · 2014 to 2015
$413k
Leptin, Obesity, and StrokeR21NS083692 · NINDS · UNIVERSITY OF KENTUCKY · PI MURPHY, MICHAEL PAUL · 2014 to 2015
$413k
Leptin Signaling and Alzheimer's DiseaseR21AG045809 · NIA · UNIVERSITY OF KENTUCKY · PI MURPHY, MICHAEL PAUL · 2014 to 2015
$408k
NIA NIH HHS R21 AG045809NIEHS NIH HHS R21 ES024158NINDS NIH HHS R21 NS083692
6 · The paper itself

Abstract

backgroundVascular contributions to cognitive impairment and dementia (VCID) is a complex form of dementia, combining aspects of vascular disease and other forms of dementia, such as Alzheimer's disease. VCID encompasses a wide spectrum of cerebrovascular-driven cognitive impairment, from mild cognitive impairment to fully developed dementia. This disease state is further complicated by metabolic disorders, such as type 2 diabetes and hypertension, and lifestyle factors, like obesity and high fat diets. SCOPE OF REVIEW: This manuscript is meant to both define VCID and review the in vitro and in vivo models of the disease state. This includes in vitro models of the neurovascular unit, models of chronic cerebral hypoperfusion, animals with NOTCH3 mutations as a model of small vessel disease, large animals with cerebral amyloid angiopathy (CAA), and animal models of mixed dementia. MAJOR

conclusionsSynthetic microvessels are a promising technique to study the neurovascular unit and canines, despite the cost, are an excellent model to study CAA. While there are several good models of individual aspects of VCID, the heterogeneity of the disease states prevents them from being a model of all aspects of the disease. Therefore, VCID needs to be further defined into disease states that exist within this umbrella term. This includes specific guidelines for stroke counts and stroke locations and further categorization of overlapping cerebrovascular and AD pathologies that contribute to dementia. This will allow for better models and a more thorough understanding of how vascular disease contributes to dementia. GENERAL SIGNIFICANCE: VCID is the second most common form of dementia and is expected to increase in coming years. The heterogeneity of VCID makes it difficult to study, but without better definitions and models, VCID presents a major public health problem for our aging population. This article is part of a Special Issue entitled: Vascular Contributions to Cognitive Impairment and Dementia, edited by M. Paul Murphy, Roderick A. Corriveau and Donna M. Wilcock.

Indexed as

Alzheimer DiseaseAnimalsBlood-Brain BarrierBlood Flow VelocityCell Culture TechniquesCerebral Amyloid AngiopathyCognitive DysfunctionDementia, VascularDisease Models, AnimalHumansNeurovascular CouplingVascular cognitive impairmentVascular contributions to cognitive impairment and dementiaVCIVCID

Identifiers

PMID26704178
PMCPMC4821780
OpenAlexW2220364403

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.